UNRESECTABLE FALLOPIAN TUBE ENDOMETRIOID ADENOCARCINOMA

Clinical trials for UNRESECTABLE FALLOPIAN TUBE ENDOMETRIOID ADENOCARCINOMA explained in plain language.

Never miss a new study

Get alerted when new UNRESECTABLE FALLOPIAN TUBE ENDOMETRIOID ADENOCARCINOMA trials appear

Sign up with your email to follow new studies for UNRESECTABLE FALLOPIAN TUBE ENDOMETRIOID ADENOCARCINOMA, keep track of the ones that matter, and come back to a personal dashboard instead of checking manually.

Our safety recommendation!

By submitting, you agree to our Terms of use

Not yet finished but already full! 1

New hope for Hard-to-Treat ovarian cancer? early trial tests drug combo

Disease control Ongoing

This early-stage study is testing the safety and best dose of a new drug called ipatasertib when given alongside standard chemotherapy drugs (paclitaxel and carboplatin) to patients with advanced ovarian, fallopian tube, or primary peritoneal cancer. The goal is to see if adding …

Matched conditions: UNRESECTABLE FALLOPIAN TUBE ENDOMETRIOID ADENOCARCINOMA

Phase: PHASE1 • Sponsor: National Cancer Institute (NCI) • Aim: Disease control

Last updated Mar 30, 2026 14:35 UTC

UNRESECTABLE FALLOPIAN TUBE ENDOMETRIOID ADENOCARCINOMA

Get alerted when new UNRESECTABLE FALLOPIAN TUBE ENDOMETRIOID ADENOCARCINOMA trials appear

New hope for Hard-to-Treat ovarian cancer? early trial tests drug combo